Home » FDA Holding Off on Finalizing Regulatory Guidance for Lab-Developed Tests

FDA Holding Off on Finalizing Regulatory Guidance for Lab-Developed Tests

Nov 18, 2016
|
Turna Ray

This article has been updated with additional comment from the FDA regarding a Senate committee hearing in September, and a statement from the Personalized Medicine Coalition. 

NEW YORK (GenomeWeb) – Amid post-election uncertainty, the US Food and Drug Administration has decided to delay finalizing its draft guidance on regulating lab-developed tests, GenomeWeb has learned.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Science Power and Research Fraud

The New York Times reports that as China invests in science, it also is dealing with research fraud.

This Week in PLOS

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

Just Spread Out Here

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Tianyuan Man's Genome

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.

What's Popular?

In Molecular Diagnostics

  1. UPDATE: Thermo Fisher's NSCLC Companion Dx Covered by Regence BCBS

  2. NIH to Fund Cancer MDx Development Projects

  3. Genetic Counselors Struggle With Anthem Prior Authorization Program, Increasing Denials

    Premium

  4. At FDA/AACR Liquid Biopsy Meeting, Researchers Detail Concordance Challenges, Standards

    Premium

  5. 'Digital' Nucleic Acid Amplification Shows Promise for Rapid Antibiotic Susceptibility Testing

    Premium

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.